Tata India Pharma & Healthcare IDCW Reinvest Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹5,000

Tata India Pharma & Healthcare IDCW Reinvest Direct Plan

NAV
₹34.3353
+0.70%
(21 May)
AUM
1,223 Cr
TER
0.67%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is below its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+16.6%
+7.7%
+0.3%
+0.3%
+0.3%
3Y
+24.4%
+34.8%
+35.7%
+35.7%
+35.7%
5Y
+23.8%
+34.5%
+35.1%
+35.1%
+35.1%
ALL
+14.0%
+17.9%
+12.1%
+12.1%
+12.1%
VOL
15.7%
18.0%
20.4%
20.4%
20.4%
TER
0.7%
0.6%
0.8%
0.8%
0.8%
AUM
₹1,223 Cr
₹6,485 Cr
₹5,035 Cr
₹5,035 Cr
₹5,035 Cr
INFO
0.89
1.00
0.59
0.59
0.59
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Tata India Pharma & Healthcare IDCW Reinvest (DR)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 30th Apr
Top holdings
Sun Pharmaceuticals Industries Ltd
12.8%
Cash / Net Current Asset
6.4%
Cipla Ltd
6.2%
Aurobindo Pharma Ltd
6.2%
Apollo Hospitals Enterprise Ltd
5.8%
Divi's Laboratories Ltd
5.2%
Lupin Ltd
5.2%
Fortis Healthcare Ltd
4.8%
Aster DM Healthcare Ltd Ordinary Shares
4.0%
Alkem Laboratories Ltd
3.1%
Top industry exposure
Healthcare
91.1%
Basic Materials
2.3%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹5,000
Additional lumpsum
₹1,000
Portfolio turnover
14%
Lock-in period
-
Exit load
• 0.25% for redemption within 30 days
Fund objective
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Fund manager(s)
Meeta Shetty
Rajat Srivastava

FAQs